Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019175 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00019175: Completed Phase 1 study of Melanoma (Skin), sponsored by National Cancer Institute (NCI).
NCT00019175 is a Phase 1 study of Melanoma (Skin) that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019175, a Phase 1 study of Melanoma (Skin), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from an antigen combined with a modified virus may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy with interleukin-2 may kill more tumor cells. PURPOSE: Phase I trial to compare the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have recurrent metastatic melanoma that has not responded to previous therapy.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL gp100 antigen
- BIOLOGICAL fowlpox virus vaccine vector
Study Locations (1)
Maryland
- Surgery Branch - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-08 |
| Phase | Phase 1 |
What the finished NCT00019175 record still lists
NCT00019175 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 3 interventions - of which aldesleukin is the first listed.
NCT00019175 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00019175 about?
NCT00019175 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma". RATIONALE: Vaccines made from an antigen combined with a modified virus may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy with interleukin-2 may kill more tumor cells. PURPOSE: P...
What is the current status of trial NCT00019175?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-08.
What conditions does trial NCT00019175 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00019175?
The interventions under investigation include: aldesleukin (BIOLOGICAL), gp100 antigen (BIOLOGICAL), fowlpox virus vaccine vector (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019175?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00019175 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia